Skip to main content

Table 2 Meta-analysis of the HIF-1α C1772T polymorphism and cancer risk

From: Association between HIF-1α C1772T/G1790A polymorphisms and cancer susceptibility: an updated systematic review and meta-analysis based on 40 case-control studies

Variables

  

TT vs.CC

CT vs.CC

CT + TT vs.CC

TT vs.CT + CC

T vs.C

Study

Case/control

I 2

Phet

OR (95% CI)

Case/control

I 2

Phet

OR (95% CI)

Case/control

I 2

Phet

OR (95% CI)

case/control

I 2

Phet

OR (95% CI)

Case/control

I 2

Phet

OR (95% CI)

Overall

40

9301/12392

67

<0.001

1.63 (1.02-2.60)*

10562/14078

68

<0.001

1.08 (0.92-1.26)*

10958/14676

70

<0.001

1.15 (1.01-1.34)*

10540/12470

71

<0.001

2.11 (1.32-3.37)*

21738/28578

76

<0.001

1.21 (1.04-1.41)*

Overall in HWE

31

7429/9947

59

0.02

2.21 (1.27-3.83)*

8481/11109

64

<0.001

1.15 (0.98-1.36)*

8604/11556

70

<0.001

1.20 (1.02-1.41)*

8275/9350

49

0.01

2.13 (1.28-3.55)*

17208/22338

76

<0.001

1.22 (1.03-1.44)*

Cancer type

Cervical

3

664/750

66

0.09

10.11 (2.55-40.05)

739/871

60

0.08

0.98 (0.72-1.34)

749/874

80

0.01

1.32 (0.61-2.87)*

749/874

51

0.15

8.55 (2.28-32.13)

2369/1748

88

<0.001

1.41 (0.59-3.35)*

Breast

6

1859/1809

62

0.03

1.41 (0.34-5.75)*

2117/2033

37

0.16

1.01 (0.91-1.33)

2143/2046

46

0.1

1.13 (0.94-1.36)

2143/2046

60

0.04

1.38 (0.35-5.46)*

4286/4092

56

0.04

1.09 (0.80-1.48)*

Breast in HWE

5

1784/1744

55

0.08

2.30 (1.08-4.91)

2022/1963

35

0.19

1.07 (0.88-1.29)

2047/1972

56

0.06

1.12 (0.92-1.35)

2047/1972

49

0.12

2.27 (1.06-4.82)

4154/3944

65

0.02

1.09 (0.76-1.55)*

Breast in Asian

3

1605/1564

0

0.93

4.42 (1.60-12.21)

1809/1742

36

0.21

1.14 (0.92-1.41)

1832/1746

51

0.13

1.22 (0.99-1.49)

1832/1746

0

0.91

4.16 (1.51-11.48)

3664/3492

55

0.11

1.28 (1.05-1.55)

Lung

3

375/438

75

0.04

1.41 (0.07-30.44)*

471/553

75

0.02

1.13 (0.59-2.19)*

509/566

86

0.01

1.19 (0.51-2.76)*

509/566

71

0.07

3.27 (1.73-6.17)

1018/1132

89

<0.001

1.19 (0.50-2.86)*

Colorectal

4

599/2123

-

-

-

624/2175

79

0.03

0.24 (0.01-5.51)*

627/2177

71

0.02

1.12 (0.57-2.18)*

627/2177

-

-

-

1254/4354

80

0.02

0.26 (0.01-6.38)*

Prostate

6

3149/3415

70

0.01

1.34 (0.54-3.31)*

3766/4032

86

<0.001

1.34 (0.93-1.92)*

3816/4084

87

<0.001

1.36 (0.95-1.96)*

3816/4084

69

0.01

1.31 (0.54-3.20)*

7632/8168

87

<0.001

1.35 (0.96-1.89)*

Prostate in HWE

4

1814/2067

59

0.09

1.57 (0.89-2.75)

2168/2417

88

<0.001

1.42 (0.84-2.40)*

2200/2438

87

0.01

1.50 (0.89-2.40)*

2200/2438

61

0.08

1.55 (0.89-2.72)

4400/4876

85

<0.001

1.44 (0.93-2.21)*

Renal

4

1015/1035

25

0.26

0.28 (0.12-1.28)

1065/1157

74

0.01

0.62 (0.31-1.24)*

1160/1241

70

0.02

0.62 (0.33-1.18)*

1160/1241

21

0.29

1.37 (0.92-2.04)

2320/2482

44

0.15

0.91 (0.73-1.12)

Renal in HWE

2

867/847

0

0.62

0.67 (0.21-2.13)

947/929

13

0.28

0.92 (0.67-1.26)

952/936

29

0.24

0.90 (0.67-1.22)

952/936

0

0.64

0.69 (0.22-2.17)

1904/1872

37

0.21

0.89 (0.67-1.19)

Oral

4

549/547

0

0.46

2.01 (0.75-5.41)

542/668

50

0.14

0.90 (0.55-1.47)

589/679

16

0.3

1.04 (0.66-1.64)

589/679

93

<0.001

22.82 (0.28-1887.72)*

1178/1358

88

<0.001

2.52 (0.71-8.98)*

Oral in HWE

2

446/423

-

-

-

478/443

0

0.5

1.28 (0.69-2.38)

479/443

0

0.4

1.35 (0.73-2.49)

479/443

-

-

-

958/886

0

0.32

1.41 (0.78-2.56)

Other

12

1033/2151

30

0.2

3.18 (1.90-5.32)

1190/2445

67

<0.001

1.18 (0.79-1.78)*

1276/2622

60

<0.001

1.34 (0.95-1.87)*

1276/2622

0

0.52

3.31 (1.98-5.53)

2434/4940

58

0.01

1.47 (1.10-1.96)*

Other in HWE

9

880/1032

56

0.08

5.10 (1.72-15.07)

1032/1758

60

0.01

1.47 (0.97-2.21)*

1041/1763

64

0.01

1.52 (0.99-2.34)*

1041/1763

24

0.27

4.47 (1.53-13.00)

2082/3526

67

0.01

1.52 (1.02-2.28)*

Ethnicity

Asian

20

5124/5781

0

0.96

4.10 (2.49-6.76)

5678/6335

50

0.01

1.20 (0.99-1.46)*

5787/6400

75

<0.001

1.29 (1.04-1.58)*

5787/6400

0

0.98

3.67 (2.23-6.02)

11574/12800

61

<0.001

1.28 (1.04-1.57)

Caucasian

16

1791/4247

74

<0.001

1.54 (0.72-3.27)*

2220/4781

76

<0.001

0.93 (0.65-1.33)*

2385/4921

59

0.01

1.07 (0.80-1.43)*

2385/4921

58

0.003

1.95 (1.14-3.31)*

4770/9842

78

<0.001

1.20 (0.91-1.57)

Caucasian in HWE

9

1473/3153

76

<0.001

2.28 (0.62-8.35)*

1738/3152

79

<0.001

1.20 (0.99-1.46)*

1776/3535

82

<0.001

1.28 (0.88-1.86)*

1776/3535

69

0.002

2.08 (0.68-6.37)*

3552/7070

86

<0.001

1.34 (0.86-2.07)

Source of control

HB

17

4608/5249

77

<0.001

3.28 (1.29-8.30)*

5259/6029

60

<0.001

1.18 (0.96-1.45)*

5348/6086

72

<0.001

1.28 (1.01-1.62)*

5348/6086

71

<0.001

2.85 (1.24-6.54)*

10696/12172

80

<0.001

1.33 (1.04-1.71)*

HB in HWE

15

3340/3962

35

0.13

4.88 (2.96-8.04)

3748/4467

56

0.01

1.24 (0.99-1.57)*

3810/4488

67

<0.001

1.33 (1.02-1.74)*

3810/4488

4

0.4

4.23 (2.58-6.93)

7620/8976

74

<0.001

1.38 (1.06-1.80)*

PB

23

4693/5303

54

0.01

1.33 (0.76-2.31)*

5303/7143

74

<0.001

0.99 (0.77-1.29)*

5521/8203

70

<0.001

1.10 (0.89-1.36)*

5521/8203

72

<0.001

2.02 (1.10-3.71)*

11042/16406

74

<0.001

1.18 (0.95-1.45)*

PB in HWE

15

4089/5985

49

0.04

1.51 (0.74-3.11)*

4733/6642

72

<0.001

1.10 (0.85-1.43)*

4794/6681

72

<0.001

1.17 (0.93-1.48)*

4794/6681

46

0.63

1.51 (1.01-2.27)

9588/13362

75

<0.001

1.14 (0.89-1.45)*

  1. HWE: Hardy-Weinberg Equilibrium; PB: population based; HB: hospital based; Phet: P value for heterogeneity. *Random-effects model was used when P value for heterogeneity test <0.05; otherwise, fixed-effects model was used.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us